VolitionRx Limited · AMEX:VNRX
VolitionRx — Technical Presentation (2021)
13 slides from VolitionRx's technical presentation, 2021
Slide 1: Heather Wilson-Robles, DVM DACVIM (Oncology)
Heather Wilson-Robles, DVM DACVIM (Oncology)
Slide 2: Introduction
Introduction Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic DNA strand biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin Chromosome Oliver J Stoetzer ", Debora M | Fersching, Christoph Salat, Oliver Steinkohl, Christian J Gabk
Slide 3: Sample handling and assay conditions
3000xg for 10 min Fasted >6hrs -80C K2-EDTA tubes 450 nm
Slide 4: Breed, age at diagnosis and H3.1 concentration
Breed Age at Diagnosis Body weight (kg) Gender Disease/Stage H3.1 Concentration at Diagnosis Australian Cattle Dog 11 36 Neutered Male Lymphoma, B cell, IVa 225.85 Mixed Breed 11 20.4 Neutered Male Lymphoma, B cell, IVa 525.61 Mixed Breed 9 37.2 Neutered Male Lymphoma, T cell, Visceral, IVb 397.26 R
Slide 5: Disease monitoring: H3.1
Disease % of dogs H3.1 Time to Time from Time to monitoring: <67.4 ng/mL (ng/mL) at lowest H3.1 CR to CR H3.1 CR lowest H3.1 Round Cell 12/12 Mean 294.97 49.5 (6-210) 35.8 (13- 28.1 (6- Tumors (71.6- 125) 85) 655.4) 100% Median 224.07 19.5 16 23 Sarcomas 3/5 Mean 227.97 181.5 (81- 129 (24- 123.6 (7-
Slide 6: Disease monitoring: H3.1
Disease % of dogs Time to Time from CR Time to CR monitoring: <67.4 ng/mL lowest H3.1 to lowest H3.1 H3.1 Round Cell 12/12 Mean 49.5 (6-210) 35.8 (13-125) 28.1 (6-85) Tumors 100% Median 19.5 16 23 Sarcomas 3/5 Mean 129 (24- 181.5 (81-282) 123.6 (7- 282) 282) 60% Median 81 181.5 82 Carcinomas 3/3 Mea
Slide 7: Disease at clinical remission
Disease at Time to H3.1 (ng/mL) at CRP (mg/dL) TK (ng/mL) clinical CR (days) CR at CR CR remission* Round Cell Mean 28.1 (6- 294.97 (71.6- 23.3 (3-75.1) 2.038 Tumors 85) 655.4) (0.74-3.51) Median 23 224.07 16.7 1.98 Sarcomas Mean 123.6 (7- 227.97 (40.8- 11.7 (9.9- 1.827 282) 646.6) 15.3) (0.19-3.85)
Slide 8: Disease at clinical remission
Disease at Time to H3.1 (ng/mL) at CRP (mg/dL) TK (ng/mL) clinical CR (days) CR at CR CR remission* Round Cell Mean 28.1 (6- 294.97 (71.6- 23.3 (3-75.1) 2.038 Tumors 85) 655.4) (0.74-3.51) Median 23 224.07 16.7 1.98 Sarcomas Mean 123.6 (7- 227.97 (40.8- 11.7 (9.9- 1.827 282) 646.6) 15.3) (0.19-3.85)
Slide 9: Trends in Nucleosome Concentrations During Treatment for LSA
17a) a ok = © x< LL > <e) > aa) —Y— sD) 17a) © O Trends in Nucleosome Concentrations During Treatment for LSA CRP (mg/L) — Represents 67.4 ng/mL —= CRP -e Nucleosomes + TK VETERINARY MEDICINE & BIOMEDICAL SCIENCES TEXAS A&M UNIVERSITY A][M
Slide 10: Case Study Examples: Multiple Myeloma
H3.1 and TK (ng/mL) 300- nD So So n 100 Case Study Examples Trends in Nucleosome Concentrations During Treatment for Mult. Myeloma 14 OQ a 12 VU = 3 i} 2 £ -10 a ee Ae A 2 ) FEES LXoOSLLELSLES&LEE DD ES eSsceeeee eee oces BET TCTCS CTT TTT Gow EE SecesceseVecesceseeecececce ZY ga2encafaascaaacaaae &
Slide 11: Case Study Examples: OSA
Case Study Examples Trends in Nucleosome Concentrations During Treatment for OSA = 3007 100 £ > +80 Oo 2) % 200-4 g Leo 6 = 8 40 a ~ TK ® 2 3 100 fF -® Nucleosomes 2 |= +20 —& CRP 3 020 —— Represents 67.4 ng/mL x= 0S rt . SO oP WP oF 9 9% 2 0 PP OL FPF FFM CMW S LVR Or? <= SS i) & VETERINARY MEDICIN
Slide 12: Case Study Examples: Grade III Pulmonary Carcinoma
Case Study Examples Trends in Nucleosome Concentrations During Treatment for Grade III Pulmonary Carcinoma 1505 -40 _ -e H3.1 (ng/mL) = 30 -& CRP (mg/L) 2 100+ 9 -« TK (ng/mL) a] x (} 20 GO Represents 67.4 ng/ z a mL «6 504 £ < =10 oe x 0 0 Diagnosis Carboplatin> Carboplatin- Carboplatin-7 Carboplat
Slide 13: Nu.Q can be used to monitor for disease response and progression
• Nu.Q® can be used to monitor for disease response and progression. • H3.1 concentrations reached normal levels below 67.4 ng/mL in most patients achieving clinical remission. • H3.1 concentrations lag behind physical exam findings for clinical remission and may serve as a more sensitive measuremen